JLPC(SH:600513)2016-10-27 16:00Financial Performance - Net profit attributable to shareholders increased by 20.93% to CNY 45,708,470.25 for the first nine months of the year[6] - Operating revenue decreased by 5.47% to CNY 469,739,093.54 for the first nine months of the year[6] - The company reported a significant increase in prepayments, rising to CNY 40,013,356.01 from CNY 11,719,658.33[18] - The company reported an operating profit of CNY 18,825,179.33, up from CNY 14,925,534.79, representing a growth of approximately 26.5%[27] - Net profit for the period was CNY 16,328,606.27, compared to CNY 13,999,582.26 in the same period last year, marking an increase of about 19%[27] - The total comprehensive income attributable to the parent company for Q3 2016 was ¥16.34 million, an increase of 16.7% from ¥13.99 million in the same period last year[31] Assets and Liabilities - Total assets increased by 3.32% to CNY 1,033,800,434.88 compared to the end of the previous year[6] - The company's total liabilities were reported at CNY 223,353,367.53, down from CNY 225,662,360.13 at the beginning of the year[21] - Total current assets increased to CNY 531,093,793.20 from CNY 497,898,156.37, representing a growth of approximately 6.5%[24] - Total liabilities increased to CNY 135,416,107.84 from CNY 103,136,605.85, reflecting a growth of approximately 31.2%[25] - The company's total assets reached CNY 914,215,107.15, up from CNY 858,312,243.62, indicating an increase of about 6.5%[25] Cash Flow - Cash flow from operating activities remained stable with a slight increase of 0.17% to CNY 49,490,511.44[6] - Cash flow from financing activities showed a net outflow of -13,614,653.89, a decrease of 104.94% from the previous year due to non-public stock issuance completion[13] - The ending cash and cash equivalents balance was CNY 285,362,406.25, slightly down from CNY 294,523,996.70 at the end of the previous year[37] - Cash inflow from financing activities was CNY 10,000,000.00, a decrease from CNY 347,429,996.00 in the previous year, reflecting a decline of about 97.1%[37] - The company received CNY 266,868,184.79 from sales of goods and services, an increase from CNY 242,057,475.89 year-over-year, showing a growth of approximately 10.2%[36] Shareholder Information - The number of shareholders reached 21,226 at the end of the reporting period[10] - The largest shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd., holds 37.09% of the shares[10] - The equity attributable to owners increased to CNY 778,798,999.31 from CNY 755,175,637.77, reflecting a growth of approximately 3.1%[25] Investment and Expenses - Investment income dropped to 1,173,883.39, down by 73.88% compared to the same period last year[13] - The company's sales expenses for the first nine months of 2016 were ¥123.40 million, up 5.0% from ¥117.47 million in the same period last year[30] - The financial expenses for the first nine months of 2016 showed a significant improvement, reporting a net income of ¥6.08 million compared to a loss of ¥0.70 million in the same period last year[30] Operational Commitments - The company has committed to maintaining independent operations and financial management systems post-asset restructuring[14] - The company has committed to maintaining independent financial decision-making and operational autonomy from its controlling shareholder[15] - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has guaranteed that it will not provide funds to its controlling shareholder or related entities in any form[15]